secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001193125-26-131792
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo reports FY2025 net loss $100M; cash $246.6M, runway into 2028; LX2006 pivotal trial on track for 1H2026
--------------------------------------------------------------------------------

- Net loss FY2025 $100.0M ($1.86/share) vs $98.3M ($3.09/share) in FY2024; Q4 loss $20.9M ($0.27).
- R&D expenses FY2025 $63.8M vs $74.1M in FY2024; G&A $45.5M vs $31.7M.
- Cash $246.6M as of Dec 31, 2025, expected to fund operations into 2028.
- LX2006 for FA: FDA feedback on SUNRISE-FA 2 pivotal protocol expected Q2 2026; trial start 1H 2026.
- Collaboration with Johnson & Johnson for targeted cardiac AAV delivery; new CMO Dr. Narinder Bhalla appointed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000119312526131792/0001193125-26-131792-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000119312526131792/lxeo-20260330.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-131792

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer